What Happened
- Semaglutide — the active molecule in Ozempic (diabetes) and Wegovy (obesity) — had its primary patent expire in India on March 20, 2026, allowing Indian pharmaceutical companies to legally manufacture and sell generic versions without a licence from Danish originator Novo Nordisk.
- Within 24 hours of the expiry, more than 40 Indian pharmaceutical companies began launching their own versions at prices slashed by up to 90%, with over 50 brand names expected to enter the market through 2026.
- While the cost reduction dramatically expands access, experts caution that semaglutide and similar GLP-1 drugs are adjuncts to — not replacements for — lifestyle modification and exercise as the fundamental treatment for obesity and type 2 diabetes.
Static Topic Bridges
Indian Patent Law — Section 3(d) and the Anti-Evergreening Provision
The Indian Patents Act, 1970 (amended significantly in 2005 to incorporate TRIPS obligations) contains a unique provision — Section 3(d) — that prevents pharmaceutical companies from obtaining secondary patents on new forms (salts, polymorphs, derivatives) of known substances unless they demonstrate significantly enhanced therapeutic efficacy. This provision, which emerged from the landmark Novartis AG v. Union of India (2013) Supreme Court judgment, is India's primary legal instrument against "evergreening" — the practice of extending patent monopolies through minor modifications.
- Novartis case (2013): Novartis sought a patent on the beta-crystalline form of imatinib mesylate (Gleevec/Glivec, a cancer drug). The Supreme Court, interpreting Section 3(d), held that increased bioavailability alone does not constitute enhanced efficacy and rejected the patent — a landmark for global access to medicines.
- Section 3(d) and semaglutide: Novo Nordisk could not use secondary patents (on delivery systems, new formulations) to meaningfully extend exclusivity in India — Section 3(d) limited the scope of follow-on patents.
- TRIPS Agreement (Trade-Related Intellectual Property Rights): A WTO agreement (1994) that mandates minimum 20-year patent protection for inventions in all WTO members. India incorporated TRIPS into the Patents Act via a 2005 amendment, but used TRIPS-flexibilities like Section 3(d) to balance IP protection with public health.
- Compulsory Licensing — Section 84 of the Patents Act: Allows a third party to use a patented invention without the patentee's consent if: (a) the patented invention is not available to the public at a reasonably affordable price; (b) it is not worked in India; or (c) public interest demands it. In the semaglutide case, compulsory licensing was not needed because the primary patent expired — but it remains a tool for future drug access situations.
Connection to this news: The semaglutide patent cliff demonstrates Section 3(d) working as intended — once the primary patent expires, there is no web of secondary patents to navigate. India's generic manufacturers can enter immediately, collapsing prices by 90% and expanding access for the 250+ million adults with obesity and 101 million with diabetes.
GLP-1 Receptor Agonists — The Science of Semaglutide
Semaglutide belongs to the class of Glucagon-Like Peptide-1 (GLP-1) receptor agonists — drugs that mimic a naturally occurring gut hormone (GLP-1) released after meals. The mechanism involves slowing gastric emptying, reducing appetite signals in the brain, stimulating insulin release, and suppressing glucagon (which raises blood sugar) — producing both blood sugar control (for diabetes) and significant weight loss. Semaglutide (weekly subcutaneous injection) produces average weight loss of approximately 15% body weight in clinical trials (SUSTAIN and STEP trial programmes).
- GLP-1 receptor agonists were first developed for type 2 diabetes (Ozempic, 0.5–2 mg doses) and later approved at higher doses (2.4 mg/week as Wegovy) specifically for chronic weight management.
- WHO Essential Medicines List: Semaglutide was added to the WHO EML as a priority medicine for type 2 diabetes management, reflecting its established efficacy and safety profile.
- Side effects: Nausea, vomiting, diarrhoea — especially at initiation; rare but serious risk of pancreatitis; contraindicated in personal/family history of medullary thyroid carcinoma.
- Important limitation: These drugs suppress appetite pharmacologically but do not address the behavioural, environmental, and socioeconomic drivers of obesity — weight regain is common upon discontinuation.
Connection to this news: The patent expiry and 90% price reduction makes GLP-1 therapy accessible far beyond high-income populations, but the clinical guidance emphasises that these drugs function as add-ons to lifestyle modification, not standalone cures — a critical point for public health communication.
India's Obesity Burden and Public Health Architecture
According to NFHS-5 (2019–21), obesity and overweight have risen sharply in India: 24% of women and 22.9% of men aged 15–49 are now classified as overweight or obese (BMI ≥25 kg/m²), up from 20.6% and 18.9% respectively in NFHS-4. Abdominal obesity affects 40% of women and 12% of men. India now has approximately 101 million people with diabetes and over 250 million adults with obesity — making it one of the world's largest markets for anti-obesity and diabetes medications.
- National Programme for Prevention and Control of NCDs (NP-NCD): India's flagship programme targeting cardiovascular diseases, diabetes, cancer, and chronic respiratory diseases. Operates through district NCD clinics and community health centres.
- Ayushman Bharat — Pradhan Mantri Jan Arogya Yojana (PM-JAY): Provides health insurance of up to ₹5 lakh per family per year for secondary and tertiary care. Does not currently cover GLP-1 drugs for obesity (covered only for diabetes in some formularies).
- NFHS-5 (2019–21): Fifth round of the National Family Health Survey, a large-scale nationally representative survey covering health, nutrition, family planning, and domestic violence — a primary data source for India's public health policy.
- Double burden: India faces the double burden of undernutrition (especially in children and rural populations) and overnutrition/obesity (especially in urban, higher-income populations) — making a uniform nutrition policy challenging.
Connection to this news: With semaglutide's 90% price reduction, the policy question becomes whether India's NP-NCD or PM-JAY frameworks should include generic GLP-1 drugs in the public health formulary — potentially shifting from lifestyle-intervention-only approaches to pharmacological support at scale. This has both fiscal and social equity implications.
Key Facts & Data
- Semaglutide patent expiry in India: March 20, 2026
- Indian generic manufacturers launching: 40+ companies within 24 hours of patent expiry; 50+ brands expected by year-end
- Price reduction: Up to 90% below branded Novo Nordisk price
- GLP-1 mechanism: Mimics gut hormone GLP-1 — reduces appetite, slows gastric emptying, stimulates insulin, suppresses glucagon
- Average weight loss in STEP trials: ~15% of body weight with 2.4 mg/week semaglutide
- India obesity statistics (NFHS-5): 24% women, 22.9% men overweight/obese; 40% women abdominal obesity
- India diabetes burden: ~101 million adults (largest diabetic population globally)
- India obesity burden: ~250+ million adults with obesity
- Section 3(d): Bars secondary patents for new forms without "significantly enhanced efficacy"
- Novartis v. Union of India (2013): Landmark SC judgment defining Section 3(d) interpretation
- Section 84 (Compulsory Licensing): Available when drug is unaffordable, not worked in India, or public interest demands
- TRIPS Agreement: WTO, 1994; India compliance via Patents Act amendment, 2005
- WHO EML: Semaglutide listed as priority medicine for type 2 diabetes